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Relapse is a major cause of failure after allogeneic hematopoietic cell transplantation (HCT) in patients with
myelodysplastic syndromes (MDS). We analyzed the relapse pattern in 1007 patients who underwent
transplantation for MDS to identify factors that may determine the timing of relapse. Overall, 254 patients
relapsed: 213 before 18 months and 41 later than 18 months after HCT, a time point frequently used in clinical
trials. The hazard of relapse declined progressively with time since transplantation. A higher proportion of
patients with early relapse had high-risk cytogenetics compared with patients with late relapse (P ¼ .009).
Patients with late relapse had suggestively longer postrelapse survival than patients who relapsed early,
although the difference was not statistically signiﬁcant (P ¼ .07). Among 41 late relapsing patients, sequential
cytogenetic data were available in 36. In 41% of these, new clonal abnormalities in addition to pre-HCT
ﬁndings were identiﬁed at relapse; in 30% pre-HCT abnormalities were replaced by new clones, in 17.3%
the same clone was present before HCT and at relapse, and in 9.7%, no abnormalities were present either
before HCT or at relapse. Comparative chromosomal genomic array testing in 3 patients with late relapse
showed molecular differences not detectable by cytogenetics between the pre-HCT clones and the clones at
relapse. These data show that late relapses are not infrequent in patients who undergo transplantation for
MDS. The pattern of new cytogenetic alterations at late relapse is similar to that observed in patients with
early relapse and supports the concept that MDS relapse early and late after HCT is frequently due to the
emergence of clones not detectable before HCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION to 18 months of HCT, relapses may occur several years after
Allogeneic hematopoietic cell transplantation (HCT) has
curative potential for patients with myelodysplastic syn-
dromes (MDS). However, post-HCT relapse occurs in 10% to
50% of patients, dependent upon disease characteristics and
disease stage at HCT [1], and outcome in those patients is
poor [1-3]. Although most relapses are diagnosed within 12dgments on page 1572.
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ty for Blood and Marrow Transplantation.HCT. Clonal cytogenetic abnormalities, recently reclassiﬁed
into 5 risk groups [4] and incorporated into the revised In-
ternational Prognostic Scoring System [5], are the major
determinants of disease progression [6-8] and relapse after
HCT [1,9]. Further, recent molecular studies have aimed at
deﬁning the role of somatic mutations in determining
prognosis [10-12]. On that basis, molecular data inform
newer prognostic models to discriminate distinct risk groups
among patients with similar predicted outcome based on
conventional clinical and cytogenetic characteristics [13].
Data on the impact of molecular abnormalities in the
setting of HCT for MDS are still limited [13,14]. However,
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sible for relapse after HCT often differ from those identiﬁed
before HCT [15], although the presentation at late relapse is
not well deﬁned. We analyzed relapse patterns in 1007 pa-
tients who underwent transplantation for MDS in an attempt
to identify factors that may determine “early” versus “late”
relapse. In a limited number of patients with late relapsewho
had sequential marrow samples available, we also used
chromosomal genomic array testing (CGAT) to characterize
molecular features at relapse in comparison to pre-
transplantation ﬁndings.
MATERIALS AND METHODS
Patients and Materials
Consecutive patients with MDS, including patients whose disease had
transformed to acute myeloid leukemia (AML), who underwent trans-
plantation at the Fred Hutchinson Cancer Research Center (FHCRC) from
1984 through 2011 were included. Patients were followed by the long-term
follow-up unit of the FHCRC; in addition, patients provided follow-up in-
formation andmarrow samples through their local hematologist/oncologist.
All patients had signed informed consent as required by the FHCRC insti-
tutional review board. Bone marrow and peripheral blood cell ﬂow cyto-
metric, pathologic, and cytogenetic analyses were carried out by standard
techniques, as previously described [1,4]. Relapse was assessed over a
continuous time axis; late relapse was deﬁned as recurrence of MDS (by
morphology, cytogenetics, or both) in patients who had been in sustained
remission for at least 18months after allogeneic HCT, a time point frequently
used for evaluation in clinical trials.
DNA Extraction
Sources of DNA for CGAT included fresh frozen marrow, archived ﬁxed
cell pellets, and unstained dried smears of bonemarrow aspirates. DNA from
fresh bone marrow and fresh frozen marrow aspirates was extracted using
the Qiagen-PureGene method (Qiagen, Germantown, MD) according to the
manufacturer’s protocol. For DNA extraction from archived samples, cell
pellets in methanol/acetic acid ﬁxative were washed 3 times with cold PBS,
resuspended in 100 mL of PBS, and loaded onto the Qiagen EZ1 Advanced XL
according to the Qiagen EZ1 Virus Mini Kit v2.0. Elution volume was 60 mL.
Extraction was performed per manufacturer guidelines. DNA was stored at
4C.
DNA quality was assessed using a NanoDrop 2000 Spectrophotometer
(Thermo Scientiﬁc, Waltham, MA), which measures DNA concentration and
purity by 260/280 nm readings. The DNAwas also visualized on a 1% agarose
gel with ethidium bromide to detect/exclude degradation. The criteria for
acceptable DNA quality included visible bands by 1% agarose gel and 260/
280 nm range of 1.4 to 2.0.
CGAT
CGAT, a combination of comparative genome hybridization and single
nucleotide polymorphism (SNP) array, was used for the detection of DNA
copy number aberration or SNP using CytoScan HD (Affymetrix, Santa Clara,
CA) according to the manufacturer’s protocol. The size ﬁlter for an abnormal
call was 100 Kb (and 25 probes) for copy number aberration and 10 Mb for
copy neutral loss of heterozygosity.Statistical Analysis
Cox regression was used to assess risk factors for the cause-speciﬁc
hazard of late relapse among patients who survived without relapse for at
least 18 months. Among those who relapsed, patients were categorized as
having early (before 18 months) or late (beyond 18 months) relapse, and
logistic regression was used to examine differences in factors between the 2
groups. Factors examined for each of these purposes included those that
were deﬁned previously [16]. Overall survival was estimated using the
Kaplan-Meier method [17]. Relapse and nonrelapse mortality (NRM) esti-
mates were summarized using cumulative incidence estimates, with NRM a
competing risk for relapse and relapse a competing risk for NRM [18]. In
addition, we carried out a Fine-Gray regression analysis to assess risk factors
for late relapse [19].Figure 1. Cumulative incidence of relapse (A) and hazard of relapse over time
(B).RESULTS
Relapse and Survival
Among the 1007 patients included, 34 were alive without
relapse at last contact (less than 18 months aftertransplantation) and, therefore, were not included in the
analysis. Among the 973 remaining patients, there were 254
relapses for a cumulative incidence of 25% (Figure 1A), with
213 occurring before and 41 after 18 months. A total of 408
patients survived to 18 months without relapse. The hazard
of relapse among all 973 patients progressively declined over
time, with no clear inﬂection point identiﬁed (Figure 1B).
However, based on inspection of the cumulative incidence
curve and the frequent use of 18-month outcome as an
endpoint in clinical trials, we adhered to the 18-month time
point to separate early and late relapses.
Among the 213 early relapses, the median time to relapse
was 100 (range, 14 to 533) days, with 93% of these relapses
occurring within 1 year of HCT. Among the 41 patients who
relapsedbeyond18months, themedian time to relapsewas2.6
(range,1.5 to12.5) years.Of note, 6 patients (13%)were found to
have extramedullary relapse, 4 of whom had no evidence of
bonemarrow involvement. Among the 213 patients with early
relapse, 133 had complete cytogenetic records both before
transplantation and at the time of relapse. This subset was
subjected to comparative karyotype analysis (Figure 2).
Extended survival after relapse was infrequent in both
groups, with only 27 of 213 patients (12.7%) with early
relapse and 5 of 41 (12.2%) with late relapse surviving at last
contact (Figure 3). The median survival (after relapse) was 91
days among patients relapsing early and 220 days among
those relapsing more than 18months after HCT (P¼ .07). Five
Figure 2. (A) Bone marrow karyotypes before HCT (broken pie chart) and at the time of relapse (intact pie charts) in 213 patients with early relapse. (B) Bone marrow
karyotypes before HCT (broken pie chart) and at the time of relapse (intact pie charts) in 41 patients with late relapse.
C.C.S. Yeung et al. / Biol Blood Marrow Transplant 21 (2015) 1565e1575 1567of the 27 patients surviving after early relapse and 2 of the 5
patients surviving after late relapse were in remission after
second HCT.
Predictors of Late Relapse
Risk factors for late relapse were assessed among the 408
patients who were alive without relapse at 18 months. Re-
sults from a multivariable regression model are summarized
in Table 1. The risk of late relapse was higher among patients
whoseMDS had transformed to AML relative to patients withMDS, and risk was lower among patients with preceding
chronic graft-versus-host disease (GVHD) than among those
without chronic GVHD (modeled as a time-dependent co-
variate). Late relapse was also less frequent among patients
with refractory anemia (RA), RA with ring sideroblasts, or
refractory cytopenia with multilineage dysplasia relative to
those with RA with excess blasts (RAEB), RAEB with trans-
formation (RAEBT), or transformation to AML. An analysis
using Fine-Gray regression yielded virtually identical results
(data not shown).
Figure 3. Probability of survival in patients after early and late relapse.
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versus Late Relapse
Among the 254 patients who relapsed, we determined
characteristics that might differ between patients with early
and late relapse (Table 2). As summarized in Table 3, where
the odds ratio reﬂects the odds of late relapse relative to the
odds of early relapse, only a few differences were noted.
Patients with very poorerisk cytogenetics were less likely to
have late relapse (ie, more likely to relapse early) than those
with lower risk cytogenetics (P ¼ .006), and patients condi-
tioned with reduced-intensity regimens tended to relapse
earlier (P ¼ .06).Features of Late Relapse
We were particularly interested in the characteristics of
late relapse. Figure 2 and Table 4 summarize data on the 41
cases with late relapse; 36 with sequential marrow samples
for genetic analysis. Patients underwent transplantation
primarily from HLA-matched related or unrelated donors,
and most were conditioned with busulfan and cyclophos-
phamide. Two patients had undergone a prior HCT: patient
number 2 had received an autologous HCT for AML; when
she subsequently developed presumably therapy-related
MDS, she received a second transplant from an HLA-
mismatched unrelated donor. Patient number 3 had previ-
ously received an HLA-matched HCT from a related donor. All
patients had received peripheral blood ormarrowas a source
of stem cells.Table 1
Predictors of Late Relapse (Multivariable Regression Model)
Factor Hazard Ratio 95% CI P Value
FAB/WHO classiﬁcation
RAEB/RAEBT/tAML 1 d
RA/RARS/RCMD .35 .18-.68 .002
Disease category
MDS 1 d
tAML 2.48 1.31-4.68 .005
Chronic GVHD
No 1 d
Yes* .48 .26-.88 .02
CI indicates conﬁdence interval; FAB, French-American-British; WHO,
World Health Organization; RAEBT, RAEB with transformation; tAML,
transformation to AML; RARS, RA with ring sideroblasts; RCMD, refractory
cytopenia with multilineage dysplasia.
* Modeled as a time-dependent covariate.As illustrated in Table 4, most karyotypes at late relapse
(64%) harbored at least 1 of the abnormalities present before
HCT, suggesting a common clonal origin. However, in 27% of
patients, new clonal aberrations in addition to those docu-
mented before transplantation were detected, suggesting
clonal evolution. In 12.3% of patients, complex karyotypes
were observed at the time of relapse whereas cytogenetic
testing had been normal before HCT, suggesting that the
relapse represented the emergence of a previously unde-
tected/undetectable clone. In 27% of patients, cytogenetic
results before HCT and at the time of relapse were identical;
64% having an abnormal clone and 36% a normal karyotype.
One patient had an abnormal karyotype before HCT but
showed normal cytogenetics at late relapse, documented
morphologically.
Paired Genomic Analysis by CGAT
Analysis by chromosomal genomic array testing was
carried out in 3 cases with archived pre-HCTand relapse DNA
meeting quality criteria (see Methods).
Patient number 1 was a 49-year-old male with RAEB-1.
Marrow showed deletion 20q, conﬁrmed by CGAT, and a
loss of ASXL1 in nearly 100% of cells. Hewas conditionedwith
busulfan and cyclophosphamide and underwent HCT from
an HLA-matched sibling donor. MDS relapsed at 3 years and
progressed to AML, leading to the patient’s death. At relapse,
CGAT allelic data conﬁrmed mixed chimerism of donor and
host marrow cells (20% to 30% host cells by SNP allele tracks).
Deletion 20q (by CGAT) was present in 30% of total cells, and
a new loss of chromosome 7, indicative of clonal evolution,
was present in 10% of cells (Figure 4).
The course of patient number 2 is summarized in Figure 5.
Cytogenetically normal, nondysplastic AMLwas diagnosed at
age 25 years, and a complete remission was induced with
anthracycline plus cytarabine, followed by consolidation
with autologous HCT (after conditioning with a cytarabine-
based regimen). Five years later, the patient presented with
MDS, possibly therapy-related, with less than 5% marrow
blasts. Neither karyotyping nor CGATof marrow cells showed
clonal abnormalities. Two months later, follow-up cytoge-
netic evaluation showed 2 (new) translocations, t(1; 17) and
t(14; 22), in a single cell. The patient was conditioned with
busulfan and cyclophosphamide and underwent trans-
plantation from an HLA-C antigenemismatched unrelated
donor. Her MDS relapsed at 567 days, showing t(1; 17) and
t(14; 22) by karyotype. CGAT of marrow cells showed, in
addition, monosomy X and multiple large deletions and
gains involving chromosomes 2q, 6q, and 9q (Figure 5A).
ERBB4 (spanning the breakpoint on 2q) and FANCC (9q), and
ABL1 and NOTCH1 (both on 9q) were deleted. SNP allele
analysis showed mixed donor/host chimerism (approxi-
mately 1:1), indicative of relapse in host cells (Figure 5C).
Disease progression led to the patient’s death.
Patient number 3 was identiﬁed after completion of the
present cohort analysis and is included for illustration. This
64-year-old male had refractory cytopenias with multi-
lineage dysplasia with normal cytogenetics, which pro-
gressed to RAEB-1, with 8% myeloblasts on treatment with
5-azacitidine. On treatment with arsenic trioxide and eta-
nercept, his disease evolved into chronic myelomonocytic
leukemia. Cytogenetics showed partial deletion of 16q in 2 of
20 metaphases; CGAT was unremarkable. Complete remis-
sion was induced with mitoxantrone, etoposide, and cytar-
abine, and the patient underwent transplantation from an
HLA-matched related donor after conditioning with
Table 2
Patient and Disease Characteristics*
Characteristic Early Relapse Late Relapse P Value (Early versus Late) No Relapse
No. of patients 213 41 719
Age, median (range), yr 50.7 (5-75) 44.8 (1-72) .37 46.7 (1-72)
Gender, male 118 (55) 24 (59) .71 424 (59)
Secondary MDS 57 (27) 7 (17) .19 168 (23)
Cytogenetic risk .008
Very good 2 (1) 0 11 (2)
Good 71 (33) 19 (46) 341 (47)
Intermediate 30 (14) 10 (24) 141 (20)
Poor 49 (23) 7 (17) 114 (16)
Very poor 56 (26) 2 (5) 63 (9)
Unknown 5 (2) 3 (7) 49 (7)
Myeloblasts at HCT, median % 4 8
Conditioning regimens
BuCy  ATG 72 (34) 17 (41) 315 (44)
CyTBI (12 Gy)  ATG 44 (21) 13 (32) 156 (22)
FluTBI (2-4.5 Gy) 39 (18) 2 (5) 52 (7)
BuTBI (12Gy) 13 (6) 2 (5) 57 (8)
FluBu  ATG 15 (7) 2 (5) 30 (4)
BuCyTBI (12 Gy) 5 (2) 1 (2) 38 (5)
FluTBI (2Gy) þ I-131 8 (4) 1 (2) 14 (2)
FluTreo 2 (1) 0 13 (2)
Other 13 (6) 3 (7) 44 (6)
Reduced-intensity conditioning 39 (18) 2 (5) .03 52 (4)
Donor .13
HLA-matched sibling 110 (52) 28 (68) 319 (44)
HLA-matched unrelated 57 (27) 6 (15) 196 (27)
HLA-mismatched un/related 46 (21) 7 (17) 204 (28)
Acute GVHD (grades II-IV) 148 (71) 23 (61) .19 476 (69)
FAB/WHO classiﬁcation .36
RAEB/RADBT/t-AML (versus RA/RARS/RCMD) 127 (61) 28 (68) 334 (48)
Disease category MDS (versus tAML) 119 (56) 25 (61) .55 560 (78)
Source of stem cells .07
BM 85 (40) 24 (59) 389 (54)
PBSC 124 (58) 17 (41) 318 (44)
Cord 0 0 12 (2)
BU indicates busulfan; Cy, cyclophosphamide; ATG, antithymocyte globulin; TBI, total body irradiation; Flu, ﬂudarabine; Treo, treosulfan; BM, bone marrow;
PBSC, peripheral blood stem cells.
Data presented are n (%), unless otherwise indicated.
* Among the patients who relapsed, proportions in each category are compared among those with early relapse to those with late relapse with the chi-square
test (mean age is compared between early and late relapse with the 2-sample t-test).
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relapsed with AML. Cytogenetics showed partial deletion of
15q and material of undeﬁned origin on 1p and 7q. CGAT
revealed a partial loss in chromosome 15 (Figure 6) with
the genomic coordinates of 36,467,926-60,581,770 on
15q14q22.2 per human genome build 19, including TCF12, a
transcription factor that interacts with TWIST1 and functions
in gene regulation [20]. The patient was lost to follow-up.Table 3
Multivariable Logistic Regression for Late Relapse*
Factor Odds Ratio 95% CI P Value
Cytogenetic risk
Good/very good 1 d
Intermediate 1.15 .47-2.82 .76
Poor .52 .20-1.36 .18
Very poor .12 .03-.55 .006
Donor
Unrelated/mismatched related 1 d
Matched sibling 1.90 .90-4.01 .09
Conditioning intensity
High (myeloablative) 1 d
Reduced (nonmyeloablative) .24 .06-1.09 .06
Parameters considered in multivariable analysis are those depicted in
Table 2.
* Odds ratio represents odds of late relapse versus odds of early relapse
among patients who relapsed.DISCUSSION
Relapse is a major cause of failure after allogeneic HCT for
MDS, and there is no deﬁned post-HCT interval beyond
which relapse no longer occurs. The present analysis showed
that the hazard of relapse declined progressively with time,
but approached 0 only decades after HCT. There was no
detectable abrupt change in relapse hazard at any particular
time point after HCT. Although most relapses occurred early,
the incidence of relapse was still 10.1% among patients who
survived relapse-free beyond 18 months. Consistent with
previous data, relapse was more likely with more advanced
MDS and in patients whose disease had transformed to AML
[16], whereas relapse was less likely in patients who had
developed chronic GVHD [21-23].
However, only a few factors appeared to differ between
early and late relapses. The presence of high-risk cytoge-
netics, but not disease burden as determined by myeloblast
count, was signiﬁcantly associated with early relapse.
Furthermore, patients who underwent transplantation from
HLA-matched sibling donors were more likely to relapse late
rather than early. Patients who relapsed late after HCT ten-
ded to have a longer postrelapse survival than those re-
lapsing early, consistent with data reported by Mielcarek
et al. for other disease groups [24]. Presumably, this pattern
was related to the fact that patients with the highest risk
cytogenetics relapsed early after HCT, and the same high-risk
Table 4
Pretransplantation and Post-transplantation Cytogenetics in Patients with Late Relapse
Patient No. Dx Cytogenetics Pre-HCT Cytogenetics Relapse Cytogenetics Comparison of Cytogenetics
CGAT
case 1
Normal karyotype 46,XY,del(20)(q11.2q 13.1)[15]/46,XY[5] 46,XY,t(5;19)(q33;q13.3),del(20)(q .2q13.1)
[2]/46,sl,inv(3)(q21q26.2)[3]/45,sdl 7[3]/46,XY[12]
Stem þ clonal evolution
CGAT
case 2
Normal karyotype 46,XX,t(1;17)(p32;q11.2),
t(14;22)(q13;q12)[1]/46,XX[5]
46,XX,t(1;17)(p32;q11.2),t(14;22)(q 3;q12)[19]/46, XY[1] Stem þ clonal evolution
3 46,XX,t(3;3)(q21;q26)* 46,XX,t(3;3)(q21;q26),
del(22)(q12)[7]/46,XX[4]
45,X,X,add(1p),t(3;3)(q21;q26),de 22)(q12)[20] Stem þ clonal evolution
4 Normal karyotype Normal karyotype 46,XY,del(5)(q31),t(6;11)(q26;p15) el(20)(q12)[20] New abnormal clone
5 Failed to grow Failed to grow Unknown Unknown
6 Normal karyotype Normal karyotype Unknown Unknown
7 45,XY,7[15]/46,XY[3] 45,XY,7[15]/46,XY[3] 49,XY,þ4,þ8,þ13[8]/50,XY,idem,
þ22[4]/50idemþ18[2]/46,XY[5]
New abnormal clone
8 Unknown 45,XY,7[13]/46,XY[17] 42-44,XY,del(1)(p32),del(2)(p23), der(15)t(15;?)(p11;?),
17,der(17)t(17;?)(p11;?),der(21)t 1;?)(p11;?),der(22)
t(22;?)(p11;?),[cp15]/46,XX[6]
Stem þ clonal evolution
9 Unknown 43w45,XY,5,þder(5)t(5;17)
(q13;q21),del)(7)(q21),
9,þder(9)t(9;22)(p22;q11),
12,i(14)(q10),17,19,
þder(19)t(12;19)(q12;q13),
þmar[14]/46,XY[4]
43w44,XY,5,del(7)(q21),add(9)(p ),i(11)(q10),12,
14,i(14)(q10),der(17)t(5;17)(p11; 1),psu der(12)
(t(12;?;19)(p12;?;q13),22,del(22) 11),þr,1w2dmin[cp20]
Stem þ clonal evolution
10 46,XY,t(2;13)(q23-31;
q32-34)[25]/46,XY[1]
46,XY,t(2;13)(q23?33;q32-34)[19]/46,XY[1] 47,XY,t(1;7)(p32q25),t(2;13)(q?21- ;q?32-34),t(5;7)(q15;q31),
þ8, add(11)(p11),add(12)(q22)[25] 6,XY[5]
Stem þ clonal evolution
11 46,XX,del(5)(q15q33)[20] 46,XX,del(5)(q15q33)[20] Unknown Unknown
12 Normal karyotype Normal karyotype Failed to grow Unknown
13 Unknown 46,XY,r(6)(p?23q?23),del(7)(q22)[6]/47,
idem,þ21[6]/48,XY[6]
45,X,t(Y;22)(q12,?p12),t(2;5;17)(q1 ;q13;q25),
add(7)(p11),22[3]/46,XX[17]
New abnormal clone
14 Normal karyotype Normal karyotype Unknown Unknown
15 Failed to grow Failed to grow 46,XY,t(2;15)(q13;q24),der(3)t(3;1 (p13;p15),
der(11)inv(11)(p11.2;q23)t(3;11)[3 46,X,?der(Y)
t(Y;9)(q11.2;q13)t(9;21)(q22;q22), r(9)?t(Y;9)(q11.2;q13),
der(21)?t(9,21)(q22;22)[8]/46,XY,t( ;3)(?p13;?q12)[1]/46,XX[3]
Unknown
16 Normal karyotype Normal karyotype 46,XX,del(7)(q?31)[2]46,XX[29]/46 Y[6] New abnormal clone
17 46,XY,del (20)(q11.2)[8]/46,XY[11] 46,XY,del(20)(q11.2)[6]/46,XY[13] 46,XY,del(20)(q11.2q13.3)[4]/46,XY 6] Same
18 Normal karyotype Normal karyotype Normal karyotype Normal no change
19 Normal karyotype 48,XY,þ8,þ11[3]/46,XY[27] þ8,þ11q23 (FISH) Same
20 Unknown 45,XY,dic(20;20)(q11.2;p13)[6]/46,XY[14] Normal karyotype Loss of abnormal clone
21 46,XX,inv(11)(p13p15)?c 46,XX,inv(11)(p11.2p14.2)c,i(17)(q10)[19]/
46,XX,inv(11)(p11.2p14.2)c[1]
46,XX,i(17)(q10)[18]/46,XY[2] Same
22 Normal karyotype Normal karyotype Failed to grow Unknown
23 Normal karyotype Normal karyotype Normal karyotype Normal no change
24 46,XX,del(5)(q13q31)[15] 46,XX,del(5)(q13q31)[15] 46,XX,del(5)(q13q31)[15]/46,XY[5] Same
25 Normal karyotype Normal karyotype Normal karyotype Normal no change
26 Normal karyotype 46,XX,t(2;3)(p23;q28)[9]/46,XX[9] 46,XX,t(2;3)(p23;q27),del(5q)(q31q 3) [cp19]/46,XY[1] Stem þ clonal evolution
27 46,XY,add(7)(p22)[3],46,XY[7] 45,XY,?t(4;12)(q?27;p13),6,7,þr[3]/46,XY[17] Unknown Unknown
28 Failed to grow 46,XY,t[1;11) (p36;q13)[10] Unknown Unknown
29 46,X,t(X;11)(q11;p15),der(6)t(6;10)
(p22;q11.2)
[16]/45,idem,21[3]/46,XX[1]
46,X,t(X;11)(q11;p15),der(6)t(6;
10)(p22;q11.2)[4]/46,XX[16]
47,X,t(X,11)(q11;p15),t(1;2)(p21;p2 ),inv(5)(p13q13),
der(6)t(6;10)(p22;q11.2),þ8,inv(12 q13q24)[7]/46,XY[13]
Stem þ clonal evolution
30 Normal karyotype 46,XX,del(7)(q11.2)[4]/46,XX[18] 47,XX,þ4,t(4;12)(q13;q12)[17]/46,X [3] New abnormal clone
31 46,XX,þ5,t(11;19)(q23;p13.3)
[16]/46,XX(4]
46,XX,þ5,t(11;19)(q23;p13.3)[16]/46,XX[4] 47,XX,þ5,t(11;19)(q23;p13.3),add( )(p11.2)[18]/46,XX[2] Stem þ clonal evolution
C.C.S.Yeung
et
al./
Biol
Blood
M
arrow
Transplant
21
(2015)
1565
e
1575
157011
,
1
l(
,d
7,
(2
13
p1
(q
31
/4
2
1)
]/
de
1
,X
[1
3
3
)(
X
15
32
N
or
m
al
ka
ry
ot
yp
e
N
or
m
al
ka
ry
ot
yp
e
U
n
kn
ow
n
U
n
kn
ow
n
33
47
,X
Y
,þ
13
[2
0]
47
,X
Y
,þ
13
[2
0]
47
,X
Y
,þ
13
[1
9]
/4
6,
X
X
[1
]
Sa
m
e
34
47
,X
X
,þ
8[
9]
/4
6,
X
X
[1
]
47
,X
X
,þ
8[
18
]/
46
,X
X
[2
]
47
,X
X
,d
el
(2
)(
q3
3)
,t
(3
,1
9)
(p
21
;q
13
.1
),
þ8
,t
(1
1;
17
)(
p
13
;q
11
.2
),
d
el
(1
5)
(q
11
.2
q2
2)
[c
p
19
]/
46
,X
Y
[1
]
St
em
þ
cl
on
al
ev
ol
u
ti
on
35
5/
20
ab
n
or
m
al
*
*
N
or
m
al
ka
ry
ot
yp
e*
*
46
w
46
,X
Y
,
5,
6
,
7,
d
el
(7
q)
,
9,
ad
d
(3
q)
,
D
(1
3,
14
,o
r1
5)
,
1
7
an
d
/o
r
1
8,
2
0,
2
1,
þ6
-8
m
ar
[c
p
15
]*
*
C
lo
n
al
ev
ol
u
ti
on
36
45
,X
X
,
G
[1
]/
46
,X
X
[1
9]
*
*
46
,X
X
,in
v(
11
)(
p
15
q?
23
)[
19
]/
46
,X
X
[1
]
46
,X
X
,in
v(
11
)(
p
15
q?
23
)[
17
]/
46
,X
X
[3
]
Sa
m
e
37
N
ot
d
on
e
45
,X
Y
,
7[
16
]/
46
,X
Y
[4
]
45
,X
Y
,
7[
cp
4]
/4
6,
X
Y
[5
]
Sa
m
e
38
N
ot
d
on
e
Fa
ile
d
to
gr
ow
N
o
in
fo
rm
at
io
n
-b
ef
or
e
re
fe
rr
al
U
n
kn
ow
n
39
N
ot
d
on
e
46
,X
X
[2
0]
46
,X
X
[2
0]
N
or
m
al
n
o
ch
an
ge
40
46
,X
X
,þ
7,
d
er
(1
;7
)(
q1
0;
p
10
)
[1
6]
/4
6,
X
X
[4
]
N
ot
d
on
e
46
,X
Y
[6
]
U
n
kn
ow
n
41
46
,X
Y
,d
el
(5
)(
q1
3;
q3
3)
[5
]/
42
-4
5,
id
em
,a
d
d
(4
)(
q1
3)
,
7,
ad
d
(1
1)
(p
15
),
1
7,
1
8,
ad
d
(1
8)
(p
11
.2
),
ad
d
(1
9)
(p
13
),
2
0,
2
1,
ad
d
(2
1)
(p
11
.1
),
þ1
-3
m
ar
[c
p
12
]/
46
,X
Y
[1
]
46
,X
Y
,d
el
(5
)(
q1
3;
q3
3)
[6
]/
43
-4
9,
id
em
,
ad
d
(Y
)(
p
11
.3
),
ad
d
(4
)(
q1
3)
,
7,
8
,d
er
(1
1)
t(
4;
11
)(
q2
1;
p
15
),
ad
d
(1
2)
(p
12
),
1
6,
1
7,
ad
d
(1
8)
(p
11
.2
),
ad
d
(1
9)
(p
13
),
2
0,
2
1,
ad
d
(2
1)
(p
11
.1
),
þ1
4
m
ar
[c
p
14
]
U
n
kn
ow
n
U
n
kn
ow
n
D
x
cy
to
ge
n
et
ic
s
in
d
ic
at
es
cy
to
ge
n
et
ic
s
at
th
e
ti
m
e
of
d
ia
gn
os
is
of
M
D
S;
st
em
,c
lo
n
e
p
re
se
n
t
be
fo
re
tr
an
sp
la
n
ta
ti
on
;
“?
”,
u
n
d
et
er
m
in
ed
or
ig
in
of
m
at
er
ia
l;
FI
SH
,ﬂ
u
or
es
ce
in
in
si
tu
h
yb
ri
d
iz
at
io
n
.
*
St
u
d
ie
s
w
er
e
p
er
fo
rm
ed
at
an
ou
ts
id
e
in
st
it
u
ti
on
an
d
n
u
m
be
rs
of
sp
ec
iﬁ
ed
cl
on
es
w
er
e
n
ot
av
ai
la
bl
e.
*
*
St
u
d
ie
s
w
er
e
p
er
fo
rm
ed
in
19
83
an
d
19
84
an
d
co
rr
ec
ti
on
to
cu
rr
en
t
n
om
en
cl
at
u
re
is
n
ot
p
os
si
bl
e.
C.C.S. Yeung et al. / Biol Blood Marrow Transplant 21 (2015) 1565e1575 1571karyotypes are also the major determinant for disease pro-
gression including, apparently, progression after relapse [1].
Why patients who underwent transplantation from
HLA-matched sibling donors tended to relapse later than
patients who underwent transplantation from alternative
donors is not clear. There may have been fewer or less severe
GVHD-related problems, although no statistically signiﬁcant
association with GVHD was observed. It was of note that
disease stage/disease burden had no signiﬁcant impact on
the timing of relapse, underscoring the concept that disease
biology (as characterized by cytogenetics) was the deter-
mining factor [25].
Recent studies using molecular analyses indicate that the
clonal disease spectrum of MDS changes over the disease
course. Certain mutations are associated with a more
aggressive course and poorer prognosis, although there are
currently only limited data as tohow these somaticmutations
impact post-HCT outcome [10,22,23,26]. The present data,
including the results of CGAT, showconsiderable variability of
clonal composition at relapse compared with ﬁndings before
HCT, consistent with the evolution of new clones.
CGAT allows identiﬁcation of losses and gains in DNA
material that are not detectable by classic cytogenetics but
may be of prognostic signiﬁcance. For example, ASXL1 mu-
tations occur in approximately 20% of patients with MDS and
carry a poor prognosis [27]. CGAT can also aid in establishing
the diagnosis of MDS, particularly in children [28] and in
patients in whom morphology, immunophenotype, and
classic cytogenetics are inconclusive [29]. Thus, CGATmay be
an important tool, as about one half of all patients with MDS
do not show classic karyotypic abnormalities at the time of
diagnosis [30-33].
We were not able to secure quality DNA for pre-HCT
analysis by CGAT for all patients However, all 3 patients in
whom we were able to perform paired comparative CGAT
showed abnormalities that only occurred in the post-
transplantation sample. In patients number 2 and 3, the
post-transplantation ﬁndings included deletions in chro-
mosomes 15q/2q/6q/9q and a segmental gain in 9q, muta-
tions that have been observed in de novoMDS [34]. Although
CGAT has a very high resolution, we cannot exclude the
possibility that those abnormalities were present before HCT
but at levels not detectable even by this technique.
Conceivably, new technologies with higher sensitivity and
resolution, such as single-cell analysis using microﬂuidics,
deep sequencing of diseased genomes, or gene panels might
have detected such a minor clone [35].
Current data on clonal evolution with a deﬁned ancestral
clone depict linear (mother-daughter) and branched pat-
terns, ﬁtting, respectively, the concept of stepwise acquisi-
tion of genetic lesions, which contribute to disease
progression [36,37], and the concept of concurrent genetic
variability associated with an increased risk of particular
subclones that have a proliferative advantage leading to
clonal expansion while others become extinct [38-40]. Our
data show evidence of both patterns in patients who un-
derwent transplantation for MDS, suggesting that mecha-
nisms of post-HCT relapse, from a genetic point of view, may
be similar to those in the nontransplantation setting.
In summary, the present analysis of relapse after alloge-
neic HCT for MDS shows a progressive decline of relapse
hazard over time, although the incidence of relapse in pa-
tients who had survived free of relapse to 18months was still
10%. The difference in relapse kinetics between HLA-
matched sibling and alternative donor transplant recipients
Figure 4. Comparative CGAT in patient number 1. The top blue bar represents the pre-HCT CGAT copy number aberration data. The expanded excerpt from the top bar
shows del 20q in the pre-HCT sample. The bottom blue bar represents the post-HCT relapse CGAT copy number aberration data, showing a new monosomy 7 with
persistence of the del 20q. This Figure is available in color online at www.bbmt.org.
C.C.S. Yeung et al. / Biol Blood Marrow Transplant 21 (2015) 1565e15751572deserves further study. Cytogenetic and molecular analyses
conﬁrmed several patterns of disease evolution and relapse,
consistent with the concept that disease “recurrence” after
HCT could be due to survival of the original clone(s) or the
emergence of new clones.
The optimal conditioning regimen to prevent post-
transplantation relapse has not been deﬁned. Recent data
suggest that treosulfan-based regimens may reduce the
incidence of relapse [25]. However, the outcome in patients
with very poor cytogenetics is still disappointing [1].
Ongoing studies on the impact of somatic mutations on post-
transplantation survival [41] may identify new pathways
that can be exploited therapeutically to reduce the incidence
of post-transplantation relapse.ACKNOWLEDGMENTS
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